Oyster Point Pharma, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statement of cash flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Depreciation
Amortization and accretion of long-term debt related costs
Reduction in the carrying amount of the right-of-use assets
Provision for inventory obsolescence
Non-cash consideration for license revenue - related party
Change in fair value of net embedded derivative liabilities
Changes in assets and liabilities:
Accounts receivable, net
Inventory
Prepaid expenses and other assets
Other assets
Accounts payable
Operating lease right-of-use asset
Change in lease liabilities
Lease liabilities
Accrued expenses and other current liabilities
Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs
Payments of deferred offering costs
Proceeds from follow-on offering, net of issuance costs
Proceeds from long-term debt
Payment of debt issuance costs
Proceeds from the exercise of stock options and sale of common stock under the ESPP
Net cash provided by financing activities
Net increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at the beginning of the period
Cash, cash equivalents and restricted cash at the end of the period
Cash and cash equivalents
Restricted cash
Supplemental Cash Flow Information
Interest
Non-cash investing and financing activities:
Accrued property and equipment
Right-of-use assets acquired through leases
Conversion of redeemable convertible preferred stock to common stock upon closing of the initial public offering

Comments